Olaparib Clinical Trial

The New England Journal Of Medicine - Wikipedia, The Free ...
The New England Journal of Medicine (NEJM) is a medical journal published by the Massachusetts Medical Society. Videos in Clinical Medicine, peer-reviewed educational videos to teach procedures requiring skilled techniques and specialized physical examination. ... Read Article

Phase I trial Of The Oral PARP Inhibitor olaparib In ...
RESEARCH ARTICLE Open Access Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with ... Get Content Here

Cancer Center Open Clinical Trials - Susquehannahealth.org
Open Clinical Trials Trial # Title Recruitment Status Breast Cancer Phase III Study to Assess the Efficacy and Safety of Olaparib vs Placebo as Adjuvant Treatment in Patients with Germline BRCA 1 or 2 Mutations and ... Content Retrieval

Early Phase Clinical Trials With PARP Inhibitors
Early Phase Clinical Trials with PARP Inhibitors . Agent(s) Histology and Reference* BMN-673 . Olaparib + Dacarbazine: Olaparib + Liposomal Doxorubicin. Advanced Solid Tumor Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase ... View Full Source

Phase II Investigation Of A PARP Inhibitor (olaparib) In ...
ORAL PRESENTATION Open Access Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that ... Retrieve Content

PARP Inhibitors In Breast Cancer Treatment And Clinical Trials
Several clinical trials are being done to see if PARP inhibitors, in combination with other cancer treatments, can block PARP protein from damaged cancer cells. ... Read Article

PARP INHIBITORS IN OVARIAN CANCER - Mdanderson.org
Clinical benefit (incl. CA125 response) 11 (33%) 22 (66%) 24 pts at 100 mg bd: RECIST response. Clinical benefit (incl. CA125 response) 3 (13%) 10 (42%) INTERNATIONAL PHASE II TRIAL OF OLAPARIB IN BRCA ASSOCIATED OVARIAN CANCER ... Get Doc

RE: Approval Of New Therapies In The Treatment Of Ovarian ...
As a BRCA mutation carrier, I now qualified for a new clinical trial using olaparib, which I found out about from a friend with a background in oncology. I had to apply to be in the clinical trial at Dana ... Visit Document

Olaparib Combined With Chemotherapy For Recurrent Platinum ...
According to standard clinical practice. In the olaparib plus chemotherapy group, two olaparib dose reductions were allowed, trial in which olaparib maintenance monotherapy led to a signifi cant improvement in progression-free survival ... Get Document

National Cancer Drugs Fund Panel Statement - NHS England
National Cancer Drugs Fund Panel Statement 3 In conclusion, the CDF panel was correct to conclude that there is an active standard treatment to olaparib maintenance therapy. ... View This Document

Olaparib And Investigational PI3K Inhibitor BKM120 ...
Olaparib and Investigational PI3K Inhibitor BKM120 Combination clinical trial presented at the AACR Annual Meeting 2015, held April 18-22. “Several years ago, my colleagues on the Stand Up To Cancer [SU2C] Targeting the PI3K ... Fetch Content

Ciklofosfamid - Wikipedia, Slobodna Enciklopedija ...
Ciklofosfamid, (engl. Cyclophosphamide), komercijalna imena: Endoxan, Cytoxan, Neosar, Procytox, Revimmune, isto poznat kao citofosfan, je azotni iperit alkilirajući lek, iz oksazoforin grupe. ... Read Article

Information For Healthcare Professionals Studies Of olaparib ...
Information for Healthcare Professionals . Studies of olaparib in ovarian cancer (SOLO) SOLO2: A Phase 3 study of olaparib — an investigational PARP inhibitor — as ... View This Document

Marketing Authorization - Wikipedia, The Free Encyclopedia
Marketing authorization may be also withdrawn, suspended or revoked if the marketing authorization holder or its representative does not fulfill other legal or regulatory obligations necessary to maintaining of product on the market, ... Read Article

NDA 206162 Olaparib - Food And Drug Administration
NDA 206162 Olaparib Amy McKee, M.D. Clinical Team Leader Division of Oncology Products 1 1. Accelerated Approval • Confirmatory trial to verify and describe clinical benefit 2. 3 Applicant’s Proposed Indication: Olaparib is a PARP ... Return Document

PARP Inhibitors - Lawrence Berkeley National Laboratory
PARP Inhibitors in Triple-Negative Breast Cancer Iniparib is the first PARP inhibitor to be exclusively tested in metastatic TNBC. Phase I trials of iniparib as mono- ... Fetch This Document

Phase I trial Of olaparib In Combination With Cisplatin For ...
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors Clinical Practice and the AstraZeneca policy on Bioethics [18]. Study endpoints and assessments ... Fetch Content

Clinical Trials With PARP Inhibitors In Defined Diseases
Clinical Trials with PARP Inhibitors in Defined Diseases . Agent(s) Histology and Reference* BMN-673 . BMN 673 (Lt-673) (Single A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in ... View This Document

A Phase 1 trial Of The Poly(ADP-ribose) Polymerase Inhibitor ...
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or ... Access Document

Reference ID: 3675412
Clinical Trial Experience Based on the data from a drug-interaction trial (N=57), the AUC and C. max of olaparib increased by 2.7- and 1.4-fold, respectively, when olaparib was administered in combination with itraconazole, a strong CYP3A inhibitor. ... Access Full Source

ASH 2014: Brentuximab Vedotin And Autologous Stem Cell ...
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses results of recent clinical studies of brentuximab vedotin (BV) in Hodgkin lymphoma (HL). The phase III AETHERA trial is a randomised, double-blind ... View Video

1.Introduction - Food And Drug Administration
1.Introduction NDA 206162 for the New Molecular Entity (NME), The placebo-controlled randomized trial of olaparib as maintenance therapy provided additional safety information.Two randomized trials datasets from clinical trial D0818C00002, SOLO-2, the ongoing randomized double-blind, ... Fetch This Document

Edited Transcript Of IMGN Earnings Conference Call Or Presentation 29-Jan-16 1:00pm GMT
Q2 2016 ImmunoGen Inc Earnings Call ... Read News

ASTRAZENECA INITIATES PHASE III CLINICAL PROGRAMME FOR ...
AstraZeneca today announced enrollment of the first patient in the Phase III clinical programme for olaparib, an innovative oral poly ADP ribose polymerase (PARP) About the SOLO 2 trial . The SOLO 2 trial looks at olaparib as a maintenance monotherapy in patients with BRCA . ... Access Doc

OlympiA And OlympiAD: Randomized Phase III trials Of olaparib ...
OlympiA and OlympiAD: randomized Phase III trials of olaparib in patients with breast cancer and a germline BRCA1/2 mutation 331TiP A Tutt,1 J Balmaña,2,3 M Robson,4 J Garber,5 B Kaufman,6 C Geyer, Jr,7 K Saini,8 M Stuart,9 H Mann,9 PA Fasching 10,11 ... Content Retrieval